BioLargo, Inc. (BLGO)
| Market Cap | 38.32M -43.6% |
| Revenue (ttm) | 5.61M -65.6% |
| Net Income | -12.91M |
| EPS | -0.04 |
| Shares Out | 319.36M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 302,589 |
| Average Volume | 349,436 |
| Open | 0.1330 |
| Previous Close | 0.1300 |
| Day's Range | 0.1144 - 0.1330 |
| 52-Week Range | 0.1144 - 0.2337 |
| Beta | -0.09 |
| RSI | 23.46 |
| Earnings Date | May 22, 2026 |
About BioLargo
BioLargo, Inc. invents, develops, and commercializes various platform technologies. The company's technologies solve challenging environmental problems comprising per- and polyfluoroalkyl substances contamination, advanced water and wastewater treatment, industrial odor and VOC control, air quality control, and infection control. It holds various issued patents, maintains a pipeline of products, and provides full-service environmental engineering services. The company's products include Advanced Oxidation system, a water treatment device that g... [Read more]
Full Company ProfileFinancial Performance
In 2025, BioLargo's revenue was $7.77 million, a decrease of -56.32% compared to the previous year's $17.78 million. Losses were -$11.78 million, 390.4% more than in 2024.
Financial StatementsNews
BioLargo Quarterly report: Q1 2026
BioLargo has published its Q1 2026 quarterly earnings report on May 15, 2026.
BioLargo Transcript: Status update
A strategic partnership with Aquatech is accelerating PFAS solution commercialization, with a robust pipeline and global engagement. Clyra is nearing a major product launch, while Cellinity advances battery tech and financing. Operational efficiency and IP protection remain priorities.
BioLargo Subsidiary Clyra Medical Signs Exclusive Distribution Agreement with Al- Hikma FZCO for ViaCLYR(TM) Across the Middle East, North Africa, and Adjacent Markets
Agreement Extends Clyra's International Reach Through One of the Region's Premier Healthcare Distributors WESTMINSTER, CA / ACCESS Newswire / May 5, 2026 / BioLargo, Inc. (OTCQX:BLGO), a cleantech and...
BioLargo Signs Memorandum of Understanding with Aquatech to Accelerate Commercialization of PFAS Treatment Technology
WESTMINSTER, CA / ACCESS Newswire / May 4, 2026 / BioLargo Equipment Solutions & Technologies, Inc. ("BioLargo Equipment"), a subsidiary of BioLargo, Inc. (OTCQX:BLGO), an environmental engineering co...
BioLargo to Participate in a Town Hall Meeting Hosted by the BioLargo Shareholder Community on Discord on May 5, 2026
A meeting transcript will be published by 8-K prior to the market open the next day WESTMINSTER, CA / ACCESS Newswire / May 4, 2026 / BioLargo, Inc. (OTCQX:BLGO), a cleantech and life sciences innovat...
BioLargo awarded $1.2M contract to design minerals processing facility
BioLargo’s (BLGO) BioLargo Engineering, Science & Technologies has been awarded a $1.2M contract to design a pilot-scale minerals processing facility that will support the remediation and beneficial r...
BioLargo Engineering, Science & Technologies Awarded $1.2 Million Contract to Design Pilot-Scale Minerals Processing Facility for Resource Recovery
WESTMINSTER, CA / ACCESS Newswire / April 20, 2026 / BioLargo, Inc. (OTCQX:BLGO), a cleantech innovator focused on sustainable water and environmental solutions, announced that its engineering subsidi...
BioLargo Registration statement: Registration filing
BioLargo filed a registration statement on April 9, 2026, providing details about a securities offering with the SEC.
BioLargo Registration statement: Registration filing
BioLargo filed a registration statement on April 9, 2026, providing details about a securities offering with the SEC.
BioLargo CEO Dennis Calvert to Present Global Environmental Leadership Award to Robert Bilott at Nassau County PFAS Forum
BioLargo sponsors legal and technical forum on PFAS contamination; company's PFAS remediation technology to be featured on a technical panel alongside leading environmental engineering firms, followed...
BioLargo Earnings Call Transcript: Q4 2025
2025 saw a revenue decline to $7.8M and a $15.2M net loss, mainly due to the Pooph license termination, but strong liquidity and service revenue growth were maintained. Clyra Medical entered commercialization, AEC achieved regulatory validation, and Cellinity Battery advanced joint ventures, positioning for a transformative 2026.
BioLargo Annual report: Q4 2025
BioLargo has published its Q4 2025 annual report on March 5, 2026.
BioLargo Slides: Q4 2025
BioLargo has posted slides in relation to its Q4 2025 quarterly earnings report, which was published on March 5, 2026.
BioLargo Reports Annual 2025 Operating and Financial Results
A Year of Disciplined Execution as BioLargo Gained Commercialization for Several Business Segments with $3.9 Million Cash Balance at Year End WESTMINSTER, CALIFORNIA / ACCESS Newswire / March 5, 2026 ...
BioLargo Q4 2025 and Year End Earnings Results Webcast and Conference Call on Thursday, March 5th, 2026 - 12:00 PM Eastern Time
WESTMINSTER, CALIFORNIA / ACCESS Newswire / March 4, 2026 / BioLargo, Inc. (OTCQX:BLGO), a developer of sustainable technologies and full-service environmental engineering company, announced it will h...
BioLargo’s Clyra Medical highlights KOL presentation on ViaCLYR results
BioLargo (BLGO) announced that clinical experience with ViaCLYR, Clyra Medical Technologies’ advanced wound irrigation solution powered by its proprietary Clyrasept technology, was presented on Januar...
BioLargo Subsidiary Clyra Medical Highlights Key Opinion Leader Presentation of Exceptional ViaCLYR(TM) Clinical Results at Leading Wound Care Symposium
Clinical Experience Presented at Boswick Symposium Shows Rapid Wound Transformation, Enhanced Healing, and Strong Antimicrobial Performance Across Multiple Wound Types WESTMINSTER, CALIFORNIA / ACCESS...
BioLargo’s Clyra Medical secures first stocking order for ViaCLYR
BioLargo (BLGO) announced that its subsidiary, Clyra Medical Technologies, Inc., has received its first commercial stocking order from Advanced Solution for ViaCLYR, Clyra’s FDA-cleared wound irrigati...
BioLargo Subsidiary Clyra Medical Technologies Secures First Stocking Order with Advanced Solution for ViaCLYR(TM) Wound Irrigation Solution
Initial Distribution Launch Marks Transition to Revenue-Generating Operations WESTMINSTER, CALIFORNIA / ACCESS Newswire / February 9, 2026 / BioLargo, Inc. (OTCQX:BLGO), a cleantech and life sciences ...
BioLargo installs AEC PFAS treatment system at Lake Stockholm, New Jersey
BioLargo (BLGO), announced that its patented Aqueous Electrostatic Concentrator PFAS treatment system has been installed at the Lake Stockholm municipal water facility in New Jersey. The Aqueous Elect...
BioLargo Installs AEC PFAS Treatment System at Lake Stockholm, New Jersey
WESTMINSTER, CALIFORNIA / ACCESS Newswire / January 27, 2026 / BioLargo, Inc. (OTCQX:BLGO) today announced that its patented Aqueous Electrostatic Concentrator (AEC) PFAS treatment system has been ins...
BioLargo Transcript: Sidoti Micro-Cap Virtual Investor Conference
The presentation outlined a diversified portfolio of transformative technologies in battery storage, infection control, and PFAS remediation, each positioned for market leadership and monetization. Key assets are entering adoption and commercialization phases, with major partnerships, regulatory milestones, and financing events expected in the next six months.
BioLargo to Present at Sidoti's Micro-Cap Virtual Conference on Thursday January 22nd at 1pm EST
WESTMINSTER, CA / ACCESS Newswire / January 16, 2026 / BioLargo, Inc. (OTCQX:BLGO), a company that creates and commercializes sustainable technologies to solve challenging environmental and cleantech ...
BioLargo says ‘well positioned’ to gain global attention, commercial traction
BioLargo (BLGO) delivered an open letter to its stockholders, which read in part, “As the world enters what may be one of the largest infrastructure and technology investment cycles in…
BioLargo Reflects on 2025 Progress and Positions for the Next Phase of Global Infrastructure, Environmental, and Medical Innovation
WESTMINSTER, CALIFORNIA / ACCESS Newswire / December 29, 2025 / BioLargo, Inc. (OTCQX:BLGO), a cleantech innovator focused on sustainable water and environmental solutions, announced that it had deliv...